BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1078 related articles for article (PubMed ID: 12114422)

  • 1. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.
    Rajkumar SV; Mesa RA; Fonseca R; Schroeder G; Plevak MF; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Gertz MA; Kyle RA; Russell SJ; Greipp PR
    Clin Cancer Res; 2002 Jul; 8(7):2210-6. PubMed ID: 12114422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of bone marrow angiogenesis in multiple myeloma.
    Rajkumar SV; Leong T; Roche PC; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Kyle RA; Gertz MA; Greipp PR
    Clin Cancer Res; 2000 Aug; 6(8):3111-6. PubMed ID: 10955791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters.
    Bhatti SS; Kumar L; Dinda AK; Dawar R
    Am J Hematol; 2006 Sep; 81(9):649-56. PubMed ID: 16845660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculation.
    Hillengass J; Zechmann C; Bäuerle T; Wagner-Gund B; Heiss C; Benner A; Ho A; Neben K; Hose D; Kauczor HU; Goldschmidt H; Delorme S; Moehler T
    Clin Cancer Res; 2009 May; 15(9):3118-25. PubMed ID: 19366830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy.
    Kumar S; Gertz MA; Dispenzieri A; Lacy MQ; Wellik LA; Fonseca R; Lust JA; Witzig TE; Kyle RA; Greipp PR; Rajkumar SV
    Bone Marrow Transplant; 2004 Aug; 34(3):235-9. PubMed ID: 15170170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression.
    Kline M; Donovan K; Wellik L; Lust C; Jin W; Moon-Tasson L; Xiong Y; Witzig TE; Kumar S; Rajkumar SV; Lust JA
    Leuk Res; 2007 May; 31(5):591-8. PubMed ID: 16879867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
    Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
    Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.
    Cibeira MT; Rozman M; Segarra M; Lozano E; Rosiñol L; Cid MC; Filella X; Bladé J
    Cytokine; 2008 Mar; 41(3):244-53. PubMed ID: 18178097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A contribution to examination of propidium iodide and annexin V plasma cells indices in multiple myeloma.
    Scudla V; Ordeltova M; Bacovsky J; Vytrasova M; Sumna E; Martinek A; Horak P
    Neoplasma; 2003; 50(5):363-71. PubMed ID: 14628090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Rajkumar SV; Lacy MQ; Kyle RA
    Blood Rev; 2007 Sep; 21(5):255-65. PubMed ID: 17367905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expression of osteopontin and vascular endothelial growth factor in correlation with angiogenesis in monoclonal gammopathy of undetermined significance and multiple myeloma.
    Babarović E; Valković T; Budisavljević I; Balen I; Štifter S; Duletić-Načinović A; Lučin K; Jonjić N
    Pathol Res Pract; 2016 Jun; 212(6):509-16. PubMed ID: 26997492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of vascular endothelial growth factor immunoexpression in the context of adverse standard prognostic factors in multiple myeloma.
    Ribas C; Colleoni GW; Silva MR; Carregoza MJ; Bordin JO
    Eur J Haematol; 2004 Nov; 73(5):311-7. PubMed ID: 15458509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A long-term study of prognosis in monoclonal gammopathy of undetermined significance.
    Kyle RA; Therneau TM; Rajkumar SV; Offord JR; Larson DR; Plevak MF; Melton LJ
    N Engl J Med; 2002 Feb; 346(8):564-9. PubMed ID: 11856795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma.
    Ribatti D; Vacca A; Nico B; Quondamatteo F; Ria R; Minischetti M; Marzullo A; Herken R; Roncali L; Dammacco F
    Br J Cancer; 1999 Feb; 79(3-4):451-5. PubMed ID: 10027312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders.
    Kumar SK; Dingli D; Lacy MQ; Dispenzieri A; Hayman SR; Buadi FK; Rajkumar SV; Litzow MR; Gertz MA
    Br J Haematol; 2008 Apr; 141(2):205-11. PubMed ID: 18318761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow angiogenesis in multiple myeloma and its correlation with clinicopathological factors.
    Rana C; Sharma S; Agrawal V; Singh U
    Ann Hematol; 2010 Aug; 89(8):789-94. PubMed ID: 20177896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature.
    Siragusa S; Morice W; Gertz MA; Kyle RA; Greipp PR; Lust JA; Witzig TE; Lacy MQ; Zeldenrust SR; Rajkumar SV; Russell SJ; Hayman SR; Buadi F; Kumar SK; Dingli D; Dispenzieri A
    Ann Hematol; 2011 Jan; 90(1):101-6. PubMed ID: 20645101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells.
    Sezer O; Heider U; Zavrski I; Possinger K
    Haematologica; 2001 Aug; 86(8):837-43. PubMed ID: 11522540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma.
    Paiva B; Pérez-Andrés M; Vídriales MB; Almeida J; de las Heras N; Mateos MV; López-Corral L; Gutiérrez NC; Blanco J; Oriol A; Hernández MT; de Arriba F; de Coca AG; Terol MJ; de la Rubia J; González Y; Martín A; Sureda A; Schmidt-Hieber M; Schmitz A; Johnsen HE; Lahuerta JJ; Bladé J; San-Miguel JF; Orfao A; ;
    Leukemia; 2011 Apr; 25(4):697-706. PubMed ID: 21252988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple myeloma: clinical features and indications for therapy.
    Dispenzieri A; Kyle RA
    Best Pract Res Clin Haematol; 2005; 18(4):553-68. PubMed ID: 16026737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.